- Home
- LDWY vs GLMD Comparison
LDWY vs GLMD Comparison
Compare LDWY & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- GLMD
- Stock Information
- Founded
- LDWY 1990
- GLMD 2000
- Country
- LDWY United States
- GLMD Israel
- Employees
- LDWY N/A
- GLMD N/A
- Industry
- LDWY Advertising
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- GLMD Health Care
- Exchange
- LDWY Nasdaq
- GLMD Nasdaq
- Market Cap
- LDWY 9.2M
- GLMD 7.5M
- IPO Year
- LDWY 1991
- GLMD 2014
- Fundamental
- Price
- LDWY $5.15
- GLMD $1.48
- Analyst Decision
- LDWY
- GLMD Hold
- Analyst Count
- LDWY 0
- GLMD 1
- Target Price
- LDWY N/A
- GLMD N/A
- AVG Volume (30 Days)
- LDWY 5.7K
- GLMD 213.6K
- Earning Date
- LDWY 08-28-2025
- GLMD 11-13-2025
- Dividend Yield
- LDWY N/A
- GLMD N/A
- EPS Growth
- LDWY N/A
- GLMD N/A
- EPS
- LDWY 1.66
- GLMD N/A
- Revenue
- LDWY $71,244,000.00
- GLMD N/A
- Revenue This Year
- LDWY N/A
- GLMD N/A
- Revenue Next Year
- LDWY N/A
- GLMD N/A
- P/E Ratio
- LDWY $3.18
- GLMD N/A
- Revenue Growth
- LDWY 187.12
- GLMD N/A
- 52 Week Low
- LDWY $3.02
- GLMD $1.15
- 52 Week High
- LDWY $6.19
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- LDWY 50.99
- GLMD 51.13
- Support Level
- LDWY N/A
- GLMD $1.33
- Resistance Level
- LDWY $5.35
- GLMD $1.60
- Average True Range (ATR)
- LDWY 0.29
- GLMD 0.10
- MACD
- LDWY -0.25
- GLMD 0.03
- Stochastic Oscillator
- LDWY 83.20
- GLMD 66.67
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.